戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1                     Further, in mice bearing orthotopic 22Rv1 human prostate tumors, we did not find
2 tively inhibits the growth of an aggressive, orthotopic 4T1 tumor model in vivo than free DOX and GEM
3           All tracers rapidly accumulated in orthotopic 4T1luc tumors, allowing for the successful PE
4 icacy study of beta-lap-dC3 micelles against orthotopic A549 NSCLC xenograft-bearing mice showed sign
5  Moreover, metastatic progression of Myc-CaP orthotopic allografts is restricted by SPARCL1 in the tu
6 rmore, administration of SPHK1 inhibitors to orthotopic AML patient-derived xenografts reduced tumor
7 rostate cancer cells to repopulate tumors in orthotopic and heterotopic tissues.
8 nd underexpressing PHD3 were investigated in orthotopic and heterotopic tumor models.
9 gnificantly inhibits tumor growth in both an orthotopic and the PKT mouse model of PDAC.
10 umour cell growth in xenograft and syngeneic orthotopic animal models, and induces growth inhibition
11 R and its target genes in PCa cell lines and orthotopic animal tumours.
12                                       In the orthotopic BALB/cJ model, extramedullary hematopoiesis o
13 decreased the incidence of MIBCs in a murine orthotopic bladder cancer model and decreased the expres
14  inhibited cell migration in vitro and in an orthotopic brain tumor model, in accordance with the kno
15 asmid DNA loaded in DNA-CN in two aggressive orthotopic brain tumor models in rats.
16 pidly penetrate healthy brain parenchyma and orthotopic brain tumor tissues in rats.
17 uantum dots are intravenously delivered into orthotopic breast and pancreas tumors in mice by using t
18                    Tracers were tested in an orthotopic breast cancer model using 4T1luc-bearing syng
19 mal growth-factor receptor aptamer inhibited orthotopic breast cancer models.
20           Animal studies using mice carrying orthotopic breast MDA-MB-231 tumors showed that the cycl
21 or models and drug-induced alterations in an orthotopic breast tumor model.
22  to generate in vivo mouse models containing orthotopic breast tumors for in vivo SPECT/MRI and biodi
23 t treatment of immune competent mice bearing orthotopic breast tumors with anti-mouse CD47 antibodies
24                         PET/CT imaging in an orthotopic Capan-2 xenograft model--which secretes large
25            Apc(Min/+) mice and NSG mice with orthotopic cecal tumors were given vehicle (controls), P
26 es sustained suppression of tumorigenesis in orthotopic circulating tumour cell-derived tumour models
27                      In this study, using an orthotopic colorectal cancer (CRC) model, we found that
28       RT followed by IGF1R neutralization in orthotopic colorectal cancer models reduced the number o
29                                   In a mouse orthotopic colorectal cancer xenograft model, expression
30 promotes lymphangiogenesis and metastasis by orthotopic colorectal tumors in mice and reduces lymphat
31 arriers in human tumor tissues and mice with orthotopic colorectal tumors.
32                                              Orthotopic corneal transplantation was performed in heme
33                                 Mice bearing orthotopic CT-2A or GL261 gliomas received POL5551 and/o
34                                  Through the orthotopic engraftment of colon organoids we describe a
35 ized leukemia and lymphoma PDXs that undergo orthotopic engraftment, called the Public Repository of
36 olony formation, as well as tumorigenesis in orthotopic engraftments in mice.
37 er esophageal xenografts, and nude rats with orthotopic esophageal cancers in four study groups of si
38                             P < .001) of rat orthotopic esophageal cancers.
39  square millimeter +/- 0.11 P < .001) of rat orthotopic esophageal cancers.
40 hance local chemotherapy in a rat model with orthotopic esophageal squamous cancers.
41 radable nanocarriers, and in vivo testing in orthotopic experimental gliomas.
42 delivered from the systemic circulation into orthotopic F98 gliomas using MRgFUS, where they elicited
43                                       In two orthotopic GB xenograft mouse models, intracranial admin
44 al administration of CBL0137 to mice bearing orthotopic GBM prolonged their survival.
45 lood-brain/blood-tumor barriers (BBB/BTB) in orthotopic GBM xenografts and selectively disseminated t
46 nct patient-derived GSC lines and visualized orthotopic GBM xenografts in vivo after conjugation with
47 tion, and prolonged survival in mice bearing orthotopic GBM xenografts.
48 and tumor control in a high-grade transgenic orthotopic glioblastoma model.
49 construct (chNKG2D) in fully immunocompetent orthotopic glioblastoma mouse models.
50                                        In an orthotopic glioblastoma xenograft model expressing mutat
51 asanutlin resulted in synthetic lethality in orthotopic glioblastoma xenograft models.
52 stablished solid and diffuse patient-derived orthotopic glioblastoma xenografts 230- and 20-fold, res
53         Median survival time of rats bearing orthotopic glioma was significantly enhanced when cispla
54 titumor effects in treatment-naive tumors in orthotopic (grafted and genetically engineered) models o
55  hepatic artery, in contrast to conventional orthotopic HCC xenografts that receive both arterial and
56 In human xenograft models of subcutaneous or orthotopic HCC, administration of the selective SND1 inh
57        This study evaluated whether minority orthotopic heart transplant (OHT) recipients tend to be
58 lt (>/=18 years old) recipients of a primary orthotopic heart transplant performed between 2000 and 2
59 lant malignancy is a major cause of death in orthotopic heart transplant recipients.
60 for Organ Sharing) for all adults listed for orthotopic heart transplantation (2000-2015) with a list
61      Left ventricular (LV) dysfunction after orthotopic heart transplantation (OHT) is multifactorial
62 ading cause of morbidity and mortality after orthotopic heart transplantation (OHT).
63 with the diagnosis of myocarditis listed for orthotopic heart transplantation are younger, sicker, an
64                  Of 45 941 adults listed for orthotopic heart transplantation during this period, we
65 hanical circulatory support, and outcomes of orthotopic heart transplantation of these patients.
66 th patients with heart failure or those with orthotopic heart transplantation, serum levels and endot
67 om 101 patients with heart failure, LVAD, or orthotopic heart transplantation.
68    Adults aged 18 to 64 receiving first-time orthotopic heart transplants between July 2006 and Decem
69 ding cells in vitro and in a patient-derived orthotopic hepatocellular carcinoma model in mice.
70 d the ability of LDL-DHA to reduce growth of orthotopic hepatomas in rats.
71                                              Orthotopic hind-limb transplantations were performed in
72  contrast, as confirmed in three subtypes of orthotopic human lung cancer xenografts (A549, H460, and
73                                 Treatment of orthotopic human pancreatic cancer tumor-bearing NSG mic
74 in tumor progression was studied by using an orthotopic human pancreatic cancer xenograft mouse model
75  two murine models of lung cancer, including orthotopic human xenograft and Kras(LSL/G12D) mouse mode
76 administration of the MagMBs to mice bearing orthotopic human xenograft BxPC-3 tumours yielded a 48.3
77                 In this study we employed an orthotopic immunocompetent model of lung adenocarcinoma
78 etabolites increase during progression in an orthotopic immunocompetent model of lung cancer.
79                                              Orthotopic implant of CCA human cells in the liver of im
80                                     Using an orthotopic implantation model in mice, which uniquely re
81                     Our in vivo studies with orthotopic implantation models demonstrated a robust inc
82 ne in pancreatic cancer cells in culture and orthotopic implantation models.
83                                    Moreover, orthotopic implantation of PR55alpha-depleted pancreatic
84                                              Orthotopic injection in vivo of FGFR1-silenced osteosarc
85 rts of female Balb/C mice received bilateral orthotopic injections of syngeneic 67NR, 4T07, or 4T1cel
86                Tumor-xenografts derived from orthotopic-inoculation of MYB-overexpressing PC cells ex
87 into different brain regions receives highly orthotopic input.
88                                Results of an orthotopic intraperitoneal model of metastatic ovarian c
89                                              Orthotopic kidney and heterotopic heart transplantation
90                               In each group, orthotopic kidney transplantation was performed after re
91                 Results were confirmed in an orthotopic liver cancer model.
92  of unknown cause, and one patient underwent orthotopic liver retransplantation (re-OLT) procedure du
93 , benign biliary strictures (N = 112) due to orthotopic liver transplant (n = 73), chronic pancreatit
94                 He subsequently underwent an orthotopic liver transplant for definitive treatment of
95 with liver disease clinically considered for orthotopic liver transplant for different indications we
96                Even though auxiliary partial orthotopic liver transplantation (APOLT) as a technique
97 lic disorders are common complications after orthotopic liver transplantation (OLT) and may lead to i
98 mining of intraoperative hemodynamic data in orthotopic liver transplantation (OLT) can aid in the pr
99 ve previously shown that patients listed for orthotopic liver transplantation (OLT) in United Network
100    The impact of ethnicity on outcomes after orthotopic liver transplantation (OLT) is unclear.
101 und (DUS) arterial abnormalities (DAA) after orthotopic liver transplantation (OLT) often represent a
102 t antithymocyte globulin (RATG) induction in orthotopic liver transplantation (OLT) with tacrolimus m
103                            In the context of orthotopic liver transplantation (OLT), renal dysfunctio
104 tant causes of morbidity and mortality after orthotopic liver transplantation (OLT).
105  disease (ESLD) and that it increases during orthotopic liver transplantation (OLT).
106  key obstacle to expanding the donor pool in orthotopic liver transplantation (OLT).
107  (HCC) recurrence and overall survival after orthotopic liver transplantation and to identify factors
108 s operation, making it a safe alternative to orthotopic liver transplantation for patients with a wid
109                                              Orthotopic liver transplantation in the mouse is a power
110                      Despite the efficacy of orthotopic liver transplantation in the treatment of end
111                                 Setup of the orthotopic liver transplantation model comprises three m
112 ations after OLT, the Cardiovascular Risk in Orthotopic Liver Transplantation risk score, among a coh
113 ation has been proposed as an alternative to orthotopic liver transplantation to treat metabolic live
114                                              Orthotopic liver transplantation was performed using ste
115 fy factors that predict HCC recurrence after orthotopic liver transplantation.
116 s are refractory to drug therapy and require orthotopic liver transplantation.
117 y kills hepatoma cells and reduces growth of orthotopic liver tumors in rats.
118 s Slug-mediated lung cancer metastasis in an orthotopic lung metastasis mouse model.
119                          In an in vivo mouse orthotopic lung transplant model of BOS, antagonism of t
120  histocompatibility complex-mismatched mouse orthotopic lung transplant model, we investigated a cond
121 ine PGD models were studied: hilar clamp and orthotopic lung transplantation after prolonged cold isc
122         Previous studies in a mouse model of orthotopic lung transplantation suggested a requirement
123  space in human lung cancer specimens and in orthotopic lung tumors generated by injection of a LH2-e
124                                              Orthotopic malignant gliomas were established in syngene
125                 In addition, in mice bearing orthotopic malignant gliomas, inhibition with bevacizuma
126                                           In orthotopic mammary carcinoma models, ADCC enhancement wa
127                                        Using orthotopic mammary fat pad model of breast cancer (MDAMB
128                               We employed an orthotopic metastatic mouse model in which the PDA cells
129 rant subpopulations and tumor propagation of orthotopic MKN45/5FU xenografts.
130 h and promoted apoptosis of GBM tumors in an orthotopic model and improved the overall survival of tu
131 umor models, with the longest survival in an orthotopic model of aggressive brain cancer.
132 strate that penfluridol administration to an orthotopic model of breast cancer suppressed tumor growt
133 roliferation, survival, and metastasis in an orthotopic model of colon cancer in vivo Upon RSPO1 stim
134 nally, evaluating therapeutic efficacy in an orthotopic model of glioblastoma highlights the need to
135 a GARP-specific mAb limited metastasis in an orthotopic model of human breast cancer.
136 increase in per-tumor-cell uptake in a mouse orthotopic model of human triple-negative breast cancer.
137 n vitro, as well as metastasis in an in vivo orthotopic model of melanoma.
138                       We report here a novel orthotopic model of non-small cell lung cancer in rats,
139 -15 in Ras-driven tumor xenografts and in an orthotopic model of pancreatic cancer delayed tumor deve
140 ated with survival following ADT, we used an orthotopic model of Pten/Tp53 null prostate cancer.
141 tions using multiple tumor cell lines in the orthotopic model suggested the involvement of a C3/C3 re
142 urvival of ovarian cancer-bearing mice in an orthotopic model.
143  BBB passage and tumor accumulation in a GBM orthotopic model.
144 fold relative to the same formulation in the orthotopic model.
145 of VEGFR/Ang-2 could improve survival in two orthotopic models of GBM, Gl261 and U87.
146 acy studies conducted in two different mouse orthotopic models of glioblastoma illustrated how enhanc
147 reduces metastases, and prolongs survival in orthotopic models of human pancreatic cancer.
148 this association in multiple immunocompetent orthotopic models of lung cancer.
149 d restricts tumor growth in subcutaneous and orthotopic models of the disease.
150 r cells and inhibited lung metastasis in two orthotopic models, but had little or no effect on primar
151                 In preclinical studies using orthotopic models, NCL-1 and NCD-38 significantly reduce
152 or burden and metastasis in restraint stress orthotopic models.
153 odin depletion reduced lung metastasis in an orthotopic mouse breast cancer model.
154 suppresses tumor growth and metastasis in an orthotopic mouse model of ATC.
155                                        In an orthotopic mouse model of breast cancer, we have demonst
156 y reduced the tumor burden in a pre-clinical orthotopic mouse model of cervical cancer by decreasing
157                                        In an orthotopic mouse model of glioma, we found that Cic loss
158 eath of GIC and increase host survival in an orthotopic mouse model of human glioma.
159                            Using our in vivo orthotopic mouse model of lung cancer metastases, we fou
160 vitro Administration of miR-6126 mimic in an orthotopic mouse model of ovarian cancer elicited a rela
161                                        In an orthotopic mouse model of ovarian cancer, delivery of mi
162 suppressed tumor growth and metastasis in an orthotopic mouse model of pancreatic cancer.
163 of primary tumors and liver metastasis in an orthotopic mouse model of PDAC (mPDAC).
164                                     Using an orthotopic mouse model of pleural mesothelioma, we deter
165                            We have used this orthotopic mouse model to investigate the source of IL-1
166                                        In an orthotopic mouse model, IKKepsilon-silenced PDAC exhibit
167  xenograft tumor growth and metastasis in an orthotopic mouse model.
168 oroglutamine compared with the kidney in the orthotopic mouse model.
169  metastatic osteosarcoma cells in vivo in an orthotopic mouse model.
170 ongation following temozolomide treatment of orthotopic mouse models in vivo Our data indicate that m
171 eoadjuvant TSL HT combination therapy in two orthotopic mouse models of human breast cancer, MDA-MB-2
172                                           In orthotopic mouse models of melanoma and pancreatic ducta
173                           In immunocompetent orthotopic mouse models of pancreatic cancer and melanom
174 effects of itraconazole and paclitaxel using orthotopic mouse models with established EOC cells (SKOV
175  growth and cancer invasion in xenograft and orthotopic mouse models, respectively.
176 on attenuates in vivo glioblastoma growth in orthotopic mouse xenograft models and a transgenic gliob
177 2) and C-X-C chemokine receptor 4 (CXCR4) in orthotopic murine CRC models, including SL4 and CT26.
178 n brain tissue slices and in vivo testing in orthotopic murine malignant glioma revealed preserved na
179 constructed and successfully validated in an orthotopic murine tumor model.
180  BTIC in human glioblastoma specimens and in orthotopic murine xenografts of human BTIC implanted int
181  synergistically enhance tumor regression in orthotopic NSCLC mouse model.
182  three-dimensional culture and in an in vivo orthotopic nude mouse model of HNSCC through a novel tra
183 nced during premalignancy and (b) an in vivo orthotopic nude rat lung cancer model to evaluate respon
184 ancer models for drug discovery are based on orthotopic or subcutaneous tumours.
185 nto rats with syngeneic tumors and mice with orthotopic or xenograft tumors.
186                                  Analysis of orthotopic oral tumors generated by cells with reduced K
187 asis, which rely on in situ gene editing and orthotopic organoid transplantation in mice without canc
188 enoma-carcinoma sequence in vivo by using an orthotopic organoid transplantation model of human colon
189  of a novel bioengineered miR-34a prodrug in orthotopic OS xenograft tumor mouse model.
190                      Successful detection of orthotopic ovarian tumors is achieved by in vivo NIR-II
191 ed state, used these cell lines to establish orthotopic ovarian tumors, and found that inducible expr
192 nificantly enhanced survival of animals with orthotopic PaCa and cured peritoneally disseminated PaCa
193 y and prolonged survival were noted in human orthotopic pancreatic and non-small-cell lung xenograft
194 's anti-tumour efficacy was explored against orthotopic pancreatic and ovarian cancer tumours.
195 cimens and NK transfer in NSG mice harboring orthotopic pancreatic cancer xenografts, we assessed CSC
196                                              Orthotopic pancreatic transplants of ETV1-overexpressing
197      In vivo, MSN-UPA particles demonstrated orthotopic pancreatic tumor specific accumulation compar
198                      In addition, imaging of orthotopic pancreatic tumors was performed using (64)Cu-
199 odels and suppresses metastatic escape in an orthotopic pancreatic tumour model.
200 for the treatment of pancreatic cancer in an orthotopic patient-derived xenograft model.
201 rence (RNAi) screening technology for use in orthotopic patient-derived xenograft models, creating a
202                 We report the development of orthotopic patient-derived xenografts (PDXs) of HER2-exp
203 sease, here we develop a protocol to produce orthotopic patient-derived xenografts at diagnosis, recu
204 mplete response in multiple rhabdomyosarcoma orthotopic patient-derived xenografts tumours in vivo.
205 mens were received from 168 patients, and 67 orthotopic patient-derived xenografts were established f
206                            In a KRAS-induced orthotopic PDAC model, coadministration of iRGD enhanced
207                     We also used a syngeneic orthotopic PDAC mouse model to study tumor growth in the
208 urvival in both obesity-driven and syngeneic orthotopic PDAC mouse models.
209 jection or intravenous biodistribution to an orthotopic PDAC site.
210  GBMs using both in vitro assays and in vivo orthotopic preclinical models.
211 otopic tumors, and increased metastasis from orthotopic primaries and following tail vein injection w
212 camptothecin, in preclinical mouse models of orthotopic primary triple-negative breast tumor xenograf
213 les carrying paclitaxel and rubone inhibited orthotopic prostate tumor growth in nude mice, compared
214 /-27b on prostate cancer metastasis in vivo, orthotopic prostate xenografts were established using ag
215 g widespread transgene expression throughout orthotopic rat brain tumors in vivo following administra
216 cipients underwent bilateral nephrectomy and orthotopic renal transplantation (day 0).
217                               In vivo, after orthotopic RENCA cell renal transplantation, pulmonary t
218         In vivo, using a clinically relevant orthotopic resection model of primary glioblastoma and e
219                                   Thus, this orthotopic retinoblastoma model offers a new and unique
220 body enabled delineation of subcutaneous and orthotopic SCLC tumor xenografts as well as distant orga
221 prove the early posttransplant outcome after orthotopic small bowel transplantation.
222                      We treated mice bearing orthotopic syngeneic (Gl261) GBMs or human (MGG8) GBM xe
223                                           An orthotopic syngeneic mouse model resulted in tumours wit
224                                     Using an orthotopic syngeneic mouse tumor model, we make the stri
225  In vivo, CFI-402257 reduced MM growth in an orthotopic, syngeneic model, when used as a single agent
226           In vivo, tumors were induced in an orthotopic, syngeneic mouse model of advanced stage EOC.
227 pical imaging agent, spatially resolving the orthotopic tongue tumors in vivo.
228                                              Orthotopic trachea transplantations were performed betwe
229 ity and suppressed alveolar hemorrhage in an orthotopic transplant model for up to 3 h after extubati
230                             In a preclinical orthotopic transplant model of human GBM, thermoradiothe
231                        Finally, we apply the orthotopic transplantation model to characterize the clo
232 ses metastasis in intracardial xenograft and orthotopic transplantation models, and correlates with p
233 e tumor-suppressive function of PTPN23 in an orthotopic transplantation mouse model.
234 essor genes in colon epithelial cells and by orthotopic transplantation of Apc-edited colon organoids
235                                              Orthotopic transplantation of DeltaNp63alpha-expressing
236 hly efficient HCC invasion and metastasis by orthotopic transplantation of liver cancer organoids pro
237                                              Orthotopic transplantation of patient-derived organoids
238                       In a mouse model using orthotopic transplantation of patient-derived pancreatic
239 phological alterations and tumorigenicity in orthotopic transplants.
240                                      In vivo orthotopic tumor experiments showed inhibition of growth
241 y to the PARP inhibitor rucaparib and slower orthotopic tumor growth compared with Trp53(-/-) cells,
242 ion of both ADHFE1 and MYC strongly enhanced orthotopic tumor growth in MCF7 cells.
243 man and mouse breast cancer cells, decreased orthotopic tumor growth, reduced tumor angiogenesis and
244               Using two different syngeneic, orthotopic tumor implant models of breast cancer, we dis
245  hydrogels were used to treat two aggressive orthotopic tumor models in athymic nude mice: a human PC
246                                     Using an orthotopic tumor xenograft model, we demonstrated that e
247 erapy-treated human desmoplastic cancers and orthotopic tumor xenografts revealed that traditional ma
248 (G12D/+);Tgfbr2(flox/flox) (PKT) mice and in orthotopic tumor xenografts.
249 C cell proliferation in vitro and suppressed orthotopic tumorigenicity in vivo.
250 or an adenovirus encoding human VEGFC before orthotopic tumors and metastases formed.
251 e ability of PGE2 to induce CSC expansion in orthotopic tumors and to accelerate the formation of liv
252 tention of the DART nanoparticles within the orthotopic tumors compared to non-targeted versions.
253                Furthermore, subcutaneous and orthotopic tumors from both BC cell lines were successfu
254  (KPC) mice, as well as in C57BL/6 mice with orthotopic tumors grown from FC1242 cells derived from K
255  in Gd concentration in both heterotopic and orthotopic tumors using dynamic quantitative MRI.
256 e to mediate gene silencing in xenograft and orthotopic tumors via i.v. injection or aerosol inhalati
257                                              Orthotopic tumors were clearly visible on the PET/MR ima
258 as sufficient to increase the growth rate of orthotopic tumors with significant effects observed on t
259 ng cell abundance in vivo yielding increased orthotopic tumors, and increased metastasis from orthoto
260 fts (A549, H460, and H520) in mice and in an orthotopic VX2 tumor in rabbits.
261                                Compared with orthotopic xenograft assays, the novel biomaterial cultu
262 tive and specific metastasis detection in an orthotopic xenograft breast cancer model expressing the
263  importance of this complex in vivo using an orthotopic xenograft breast cancer model.
264 antly inhibits tumor growth in vivo using an orthotopic xenograft breast mouse model.
265 in subcutaneous syngeneic mouse melanoma and orthotopic xenograft lung cancer models.
266  survival of PEL bearing NOD-SCID mice in an orthotopic xenograft model as compared with either agent
267 e of these patients was used to establish an orthotopic xenograft model of glioblastoma.
268 mation and growth of metastatic tumors in an orthotopic xenograft model of prostate cancer, by greatl
269                                        In an orthotopic xenograft model, IL-35 promotes spontaneous p
270 e cell lines, and prolonged survival in both orthotopic xenograft models and mouse models of primary
271                                           In orthotopic xenograft models of pancreatic cancer, combin
272 OTCH3 activation in 12 of 24 patient-derived orthotopic xenograft models, 2 of which exhibit activati
273                               Notably, using orthotopic xenograft models, we demonstrate that combina
274 rew faster than wild-type clones in s.c. and orthotopic xenograft models.
275 oma stem cells (GSCs) using cell culture and orthotopic xenograft models.
276  were explored using murine subcutaneous and orthotopic xenograft models.
277 ib revealed in vivo antitumor efficacy in an orthotopic xenograft mouse model of two NB cell lines an
278                                         This orthotopic xenograft mouse model will enable clinically
279 ified elongation factors extends survival in orthotopic xenograft mouse models, suggesting that targe
280 x43 immunoreactivity at areas of invasion in orthotopic xenograft mouse models.
281 ith WT and F1174L activating mutation ALK in orthotopic xenograft mouse models.
282 rug significantly reduced OS tumor growth in orthotopic xenograft mouse models.
283 1 significantly inhibited tumor growth in an orthotopic xenograft NB mouse model by inducing Chk2/p53
284 ivo by enhancing dox-induced apoptosis in an orthotopic xenograft NB mouse model.
285 ited growth of cervical cancer cells derived orthotopic xenograft tumors in athymic nude mice.
286  the DRD2 inhibitor haloperidol to mice with orthotopic xenograft tumors reduced final tumor size and
287 morigenic potential in both subcutaneous and orthotopic xenograft tumour models.
288 -negative breast cancer, and patient-derived orthotopic xenografts (PDX) of human glioblastoma.
289 assess the density of glioma cells in murine orthotopic xenografts models and human brain tumors, tis
290 py experiments involved treating established orthotopic xenografts of an aggressive metastatic varian
291                                              Orthotopic xenografts of MKN45/5FU cells in the stomach
292  to the 5-FU dose, and in gastric submucosal orthotopic xenografts of MKN45/5FU cells.
293                              Patient-derived orthotopic xenografts of paediatric GBM, DIPG and adult
294                            Limiting-dilution orthotopic xenografts of these BCSCs regenerated origina
295                            Analyses of mouse orthotopic xenografts revealed that ETV1 induced signifi
296                         In human GSC-derived orthotopic xenografts, EFNB2 knock-down blocked tumour i
297 a cell proliferation in vitro, as well as in orthotopic xenografts.
298 ost survival compared with untreated GSCs in orthotopic xenografts.
299                                              Orthotopic xenotransplantation studies revealed that con
300                        Here, we developed an orthotopic zebrafish model in which retinoblastoma invas

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top